The Latest Breaking News from AstraZeneca

As North Korea battles its first known COVID outbreak, a lack of storage, chronic power shortages and inadequately trained medical staff pose acute challenges to inoculating its 25 million people - even with outside help, analysts said.

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known.

The renowned immunologist remains as upbeat about jabs – and UK life science – as he was in the depths of the pandemic

Here's a roundup of top developments in the biotech space over the last 24 hours:

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

AstraZeneca has become a household name thanks to its Covid-19 vaccine, though the company produces many other drugs to justify its $200 billion market cap.

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

More than 1,200 claims have been made to the government’s Vaccines Damages Payment Scheme, but no compensation has yet to be paid out